Moderna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLC

Moderna (NASDAQ:MRNA)‘s stock had its “hold” rating reiterated by Needham & Company LLC in a research report issued to clients and investors on Thursday, Benzinga reports.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group upped their target price on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. HSBC restated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Jefferies Financial Group restated a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research report on Thursday, March 28th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Trading Up 12.2 %

MRNA stock traded up $13.61 during trading on Thursday, reaching $125.07. 7,643,625 shares of the stock were exchanged, compared to its average volume of 4,085,756. The business has a 50 day moving average price of $103.95 and a 200-day moving average price of $93.92. The firm has a market capitalization of $47.89 billion, a price-to-earnings ratio of -10.01 and a beta of 1.57. Moderna has a 1 year low of $62.55 and a 1 year high of $142.79. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the business posted $3.61 EPS. The firm’s revenue was down 44.9% on a year-over-year basis. On average, research analysts predict that Moderna will post -7.51 earnings per share for the current year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total value of $1,624,800.00. Following the sale, the director now directly owns 2,041,931 shares of the company’s stock, valued at approximately $221,181,965.92. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the completion of the transaction, the director now owns 2,041,931 shares in the company, valued at approximately $221,181,965.92. The disclosure for this sale can be found here. Insiders have sold a total of 124,954 shares of company stock valued at $13,158,776 in the last ninety days. 15.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Ogorek Anthony Joseph NY ADV purchased a new stake in shares of Moderna during the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC raised its stake in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares during the period. Westside Investment Management Inc. purchased a new stake in shares of Moderna during the first quarter valued at approximately $32,000. Rise Advisors LLC raised its stake in shares of Moderna by 953.3% during the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares during the period. Finally, UMB Bank n.a. raised its stake in shares of Moderna by 121.8% during the first quarter. UMB Bank n.a. now owns 366 shares of the company’s stock valued at $39,000 after purchasing an additional 201 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.